PATENT CLAIM ANALYSIS

Application Number: 15938961
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "130100"]

Abstract:
The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

Claim (Index 8):
The bispecific antibody of  claim 7 , wherein said bispecific antibody comprises a first and a second heavy chain, each of said first and second heavy chain comprises at least a hinge region, a CH2 and CH3 region, wherein in said first heavy chain at least one of the amino acids in the positions corresponding to positions selected from the group consisting of K409, T366, L368, K370, D399, F405, and Y407 in a human IgG1 heavy chain has been substituted, and in said second heavy chain at least one of the amino acids in the positions corresponding to a position selected from the group consisting of F405, T366, L368, K370, D399, Y407, and K409 in a human IgG1 heavy chain has been substituted, and wherein said substitutions of said first and said second heavy chains are not in the same positions.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.42105
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15325364', '15533049', '15318023', '15318028', '14355986']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7975942288795617
- 35 USC 102 Novelty (BERT): 0.6243922876100871
- Combined Prediction Score: 0.7802740347526143
- Mean Citation Score: 488.148804
- Max Citation Score: 670.65137
- Similarity Product: 493.2054661334229

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test